NCT04722523
A Study of Cemiplimab With Chemotherapy and Immunotherapy in People With Head and Neck Cancer
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
Version history last read from ClinicalTrials.gov on Aug 31, 2026. The record was updated there on Nov 20, 2026; versions filed since then are not listed here yet.
All 21 versions: 13 with changes below, 8 re-verified with no change. See every version on ClinicalTrials.gov ↗
- Minor Trial arms changed: 2 → 3
- Notable Primary and study completion pushed from Jun 20, 2026 to Jun 20, 2027v21
- Minor Enrollment target: 30 to 40
- Interventions: Carboplatin (Drug), Cemiplimab (Drug), Cetuximab (Drug), Cisplatin (Drug), Docetaxel (Drug), Post-operative radiation therapy (Radiation)… to Carboplatin (Drug), Cemiplimab (Drug), Cetuximab (Drug), Cisplatin (Drug), Docetaxel (Drug), Paclitaxel (Drug), Post-operative radiation…
- Study arms: 1 to 2
- Minor Study sites: 6 to 7v13
- Notable Primary and study completion dates: Jun 20, 2023 to Jun 20, 2026
- Study sites revised (6)
Show 8 earlier versionsHide 8 earlier versions
- Minor Study sites revised (6)v11
- Notable Enrollment target: 10 to 30v10
- Notable Trial status: Active, Not Recruiting to Recruiting
- Site details revised at 6 of 6 sites
- Minor Trial status: Recruiting to Active, Not Recruiting
- Site details revised at 6 of 6 sites
- Minor Study sites: 5 to 6v6
- Minor Study sites revised (5)v4
- Minor Study sites: 1 to 5v3
- Notable Primary endpoint revisedv2
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Arms and interventions
Participants with locally advanced, resectable head and neck squamous cell carcinoma for which standard-of-care management would entail definitive surgery followed by adjuvant radiation +/- concurrent chemotherapy are eligible.
Participants with locally advanced, resectable head and neck squamous cell carcinoma for which standard-of-care management would entail definitive surgery followed by adjuvant radiation +/- concurrent chemotherapy are eligible.
A tertiary cohort of 20 patients with oral cavity squamous cell carcinoma (OCSCC)
Drugs: Cisplatin, Carboplatin, Docetaxel, Cetuximab, Cemiplimab, Paclitaxel
Procedures: Surgical Resection of Primary +/- Neck Dissection
Radiation: Post-operative radiation therapy
Sites
7 sites in 1 country